The Lancet Psychiatry, January 2024, Volume 11, Issue 1, Pages 1-80, e1-e3
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial - The Lancet
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial - The Lancet Respiratory Medicine
Drug Evidence Watch for Public Health Benefit
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial - The Lancet Neurology
Antipsychotic drug effective and safe in paranoid older people who usually aren't treated | UCL News - UCL – University College London
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study - The Lancet
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials - The Lancet Healthy Longevity
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study - The Lancet Rheumatology
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial - The Lancet Rheumatology
More people could benefit from antihypertensives, study finds
Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study - The Lancet Regional Health – Americas
eClinicalMedicine Home Page
Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies - The Lancet Neurology
Covid-19: Lancet retracts paper that halted hydroxychloroquine trials | Coronavirus | The Guardian
eClinicalMedicine Home Page
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis - The Lancet
The Lancet - The Lancet Oncology | Series | Drug safety in oncology Read the Series: https://hubs.ly/H0bvBYw0 Given the success of The Lancet Oncology's last series on drug safety in oncology in
The Lancet, 06 January 2024, Volume 403, Issue 10421, Pages 1-116, e1
Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study - The Lancet Neurology
Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study - The Lancet Regional Health – Americas
Pathophysiology, prevention, and treatment of medication overuse headache - The Lancet Neurology
Physicians' views of patient–planetary health co-benefit prescribing: a mixed methods systematic review - The Lancet Planetary Health
